NEW YORK (TheStreet) -- CHANGE IN RATINGS
Clovis Oncology (CLVS) was upgraded at Piper Jaffray to overweight from neutral. $100 price target. Company offered positive CO-1686 data at ASCO, Piper Jaffray said.
Con-way (CNW) was upgraded at Bank of America to buy from underperform. $46 price target. The Freight segment is improving faster than expected, BofA said.
Citrix Systems (CTXS) was downgraded at Berenberg to sell. $49 price target. Legacy business could lag, Berenberg said.Endo Health (ENDP) was downgraded at Cantor Fitzgerald to sell from hold. $30 price target. Expect a prolonged restructuring period, Cantor said. Endo Health was upgraded at Leerink Swann. $48 price target. Expectations have come down, and 2013 guidance is now achievable, Leerink Swann said. First Horizon National (FHN) was downgraded at Morgan Stanley to equal weight. There is limited near-term upside as the stock has outperformed its peers since the first quarter of 2012, Morgan Stanley said. http://www.thestreet.com/story/11942921/1/sodastream-could-be-a-threat-to-big-soda.html?kval=dontmiss
Haemonetics (HAE) was initiated with a market outperform rating at JMP Securities. The company's leading market position will be bolstered by M&A, and significant margin expansion is expected ahead, JMP said. Price target is $52. Lifepoint (LPNT) was upgraded at Credit Suisse to outperform from neutral. Nonurban hospitals are best positioned for health care reform, Credit Suisse said. LRR Energy (LRE) was downgraded to sell at TheStreet Ratings. Oracle (ORCL) was downgraded at Berenberg to sell. $28 price target. Company may lag the pace of innovation in the software sector, Berenberg said.
Realpage (RP) was downgraded to sell at TheStreet Ratings. Tenet Healthcare (THC) was upgraded at Deutsche Bank to buy. $55 price target. Stock is attractive, following the recent pullback, Deutsche Bank said. VMWare (VMW) was downgraded at Berenberg to sell. $57 price target. Company may be left behind by new technology trends, Berenberg said. WR Berkley (WRB) was upgraded at Bank of America/Merrill Lynch to buy from neutral. $46 price target. Stock is attractive, following a 12% pullback, BofA/Merrill said.
Stock Comments / EPS ChangesBrown-Forman (BF.B) estimates were reduced at UBS. Lower volume and pricing increased, said UBS.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV